Vivacta Biotechnology
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
$50MSeries A+
Role not disclosedLoading investors…
Activity from announced rounds
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
Develops multimodal foundation models for video generation and AI productivity